Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Document Sample
Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011 Powered By Docstoc
					         Rexahn Pharmaceuticals, Inc. – Product Pipeline
                      Review – Q1 2011
                                                                                          Reference Code: GMDHC1269CDB

                                                                                                Publication Date: JUN 2011




Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011                            GMDHC1269CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Rexahn Pharmaceuticals, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Rexahn Pharmaceuticals, Inc. Snapshot                                                                                 5
    Rexahn Pharmaceuticals, Inc. Overview                                                                             5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Rexahn Pharmaceuticals, Inc. – Research and Development Overview                                                      6
    Key Therapeutic Areas                                                                                             6
Rexahn Pharmaceuticals, Inc. – Pipeline Review                                                                        9
    Pipeline Products by Stage of Development                                                                         9
    Pipeline Products – Monotherapy                                                                                  10
    Pipeline Products – Combination Treatment Modalities                                                             11
Rexahn Pharmaceuticals, Inc. – Pipeline Products Glance                                                              12
    Rexahn Pharmaceuticals, Inc. Clinical Stage Pipeline Products                                                    12
         Phase II Products/Combination Treatment Modalities                                                          12
    Rexahn Pharmaceuticals, Inc.–Early Stage Pipeline Products                                                       13
         Pre-Clinical Products/Combination Treatment Modalities                                                      13
Rexahn Pharmaceuticals, Inc. – Drug Profiles                                                                         14
    Archexin                                                                                                         14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
    RX-0201 + Gemcitabine                                                                                            16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    Serdaxin                                                                                                         17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    Zoraxel                                                                                                          19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    Archexin                                                                                                         21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                21
    RX 1792                                                                                                          22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    RX-0047-Nano                                                                                                     23
         Product Description                                                                                         23
         Mechanism of Action                                                                                         23




Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011                          GMDHC1269CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Rexahn Pharmaceuticals, Inc. – Product Pipeline Review



         R&D Progress                                                                                                      23
    RX-0183                                                                                                                24
         Product Description                                                                                               24
         Mechanism of Action                                                                                               24
         R&D Progress                                                                                                      24
    RX-21101                                                                                                               25
         Product Description                                                                                               25
         Mechanism of Action                                                                                               25
         R&D Progress                                                                                                      25
    RX-3117                                                                                                                26
         Product Description                                                                                               26
         Mechanism of Action                                                                                               26
         R&D Progress                                                                                                      26
    RX-5902                                                                                                                27
         Product Description                                                                                               27
         Mechanism of Action                                                                                               27
         R&D Progress                                                                                                      27
    RX-8243                                                                                                                28
         Product Description                                                                                               28
         Mechanism of Action                                                                                               28
         R&D Progress                                                                                                      28
Rexahn Pharmaceuticals, Inc. – Pipeline Analysis                                                                           29
    Rexahn Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class                                                  29
    Rexahn Pharmaceuticals, Inc. - Pipeline Products By Target                                                             30
    Rexahn Pharmaceuticals, Inc. – Pipeline Products by Route of Administration                                            31
    Rexahn Pharmaceuticals, Inc. – Pipeline Products by Molecule Type                                                      32
Rexahn Pharmaceuticals, Inc. – Recent Pipeline Updates                                                                     33
Rexahn Pharmaceuticals, Inc. - Dormant Projects                                                                            35
Rexahn Pharmaceuticals, Inc. – Locations And Subsidiaries                                                                  36
    Head Office                                                                                                            36
Financial Deals Landscape                                                                                                  37
    Rexahn Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011                                                   37
    Rexahn Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011                                                38
    Rexahn Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011                                                          39
    Rexahn Pharmaceuticals, Inc. Detailed Deal Summary                                                                     40
         Equity Offering                                                                                                   40
         Rexahn Pharmaceuticals Completes Registered Direct Offering Of $5 Million                                         40
         Rexahn Pharmaceuticals Completes Public Offering Of $10 Million                                                   42
         Rexahn Pharmaceuticals Enters Into Co-Development Agreement With TheraTarget                                      44
         Licensing Agreements                                                                                              45
         Rexahn Pharmaceuticals Enters Into Licensing Agreement With Teva Pharmaceutical                                   45
         Rexahn Pharmaceuticals Enters Into Licensing Agreement With Korea Research Institute                              47
Appendix                                           
				
DOCUMENT INFO
Description: Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the Rexahn Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Rexahn Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Rexahn Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Rexahn Pharmaceuticals, Inc. - Brief Rexahn Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Rexahn Pharmaceuticals, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Rexahn Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Rexahn Pharmaceuticals, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Rexahn Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Rexahn Pharmaceuticals, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Rexahn Pharmac
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries